Mechanisms of therapeutic activity of multipotent cells in heart diseases

T Kh Fatkhudinov1, G B Bol'shakova, D V Goldshtein

  • 1V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia, fatkhudinov@gmail.com.

Insights

Stem/progenitor cell transplantation shows therapeutic potential for cardiovascular diseases. This analysis reviews mechanisms underlying stem cell therapy effectiveness in treating heart conditions.

Area of Science:

  • Cardiovascular Science
  • Regenerative Medicine
  • Cell Biology

Background:

  • Cardiovascular pathologies represent a significant global health burden.
  • Current treatments for cardiovascular diseases have limitations.
  • Stem/progenitor cell transplantation is an emerging therapeutic strategy.

Purpose of the Study:

  • To analyze findings on stem/progenitor cell transplantation for cardiovascular pathologies.
  • To review potential mechanisms of therapeutic activity.
  • To synthesize current knowledge on stem cell therapy in cardiology.

Main Methods:

  • Literature review of published reports.
  • Analysis of own research findings.
  • Synthesis of data on stem cell mechanisms.

Main Results:

  • Stem/progenitor cells exhibit multifaceted therapeutic mechanisms.
  • These mechanisms include paracrine signaling, immunomodulation, and direct tissue regeneration.
  • Evidence supports the efficacy of stem cell transplantation in preclinical and clinical cardiovascular studies.

Conclusions:

  • Stem/progenitor cell transplantation holds promise for treating cardiovascular diseases.
  • Understanding the underlying mechanisms is crucial for optimizing therapeutic strategies.
  • Further research is warranted to fully elucidate and harness the potential of stem cell therapy.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K